Fig. 2 HSG4112 dose-dependently reduces body weight and normalizes obesity-related parameters in HFD-induced obese mice orally administered with 10, 30, or 100 mg·kg-1 dose for 6 weeks (n = 10). Pair-fed group was daily fed at maximum of the food that HSG4112-100 mg·kg-1 group consumed a day before. a Weekly body weights. Data represent mean ± SEM. Two-way ANOVA with Tukey’s multiple comparison test was performed; ###P < 0.001 vs. Normal group and ***P < 0.001 vs. Vehicle group. b Mean daily food intake. c Representative image of mice from Normal group, Vehicle group, and HSG4112-100 mg·kg-1 group. d-f Absolute and relative (percentage of gram per body weight gram) weights of d gastrocnemius muscle, e perirenal fat, and f periepididymal fat. g Individual white adipocyte size distribution. h Representative image of histological section of periepididymal fat stained with H&E. Standard bar = 100µm. Serum concentration of i leptin, j insulin, and k glucose. For b-k, all data represent terminal values of mean ± SEM, and one-way ANOVA with Tukey’s multiple comparison test was performed; n.s. = not significant, ##P < 0.05, ###P < 0.001 vs. Normal group and *P < 0.05, **P < 0.01, ***P < 0.001 vs. Vehicle group.